Type 2 diabetes (T2D), chronic kidney disease (CKD), atherosclerotic cardiovascular disease (ASCVD), and heart failure (HF)-along with their associated risk factors-have overlapping etiologies, and two or more of these conditions frequently occur in the same patient. Many recent cardiovascular outcome trials (CVOTs) have demonstrated the benefits of agents originally developed to control T2D, ASCVD, or CKD risk factors, and these agents have transcended their primary indications to confer benefits across a range of conditions. This evolution in CVOT evidence calls for practice recommendations that are not constrained by a single discipline to help clinicians manage patients with complex conditions involving diabetes, cardiorenal, and/or metabolic (DCRM) diseases. The ultimate goal for these recommendations is to be comprehensive yet succinct and easy to follow by the nonexpert-whether a specialist or a primary care clinician. To meet this need, we formed a volunteer task force comprising leading cardiologists, nephrologists, endocrinologists, and primary care physicians to develop the DCRM Practice Recommendations, a multispecialty consensus on the comprehensive management of the patient with complicated metabolic disease. The task force recommendations are based on strong evidence and incorporate practical guidance that is clinically relevant and simple to implement, with the aim of improving outcomes in patients with DCRM. The recommendations are presented as 18 separate graphics covering lifestyle therapy, patient self-management education, technology for DCRM management, prediabetes, cognitive dysfunction, vaccinations, clinical tests, lipids, hypertension, anticoagulation and antiplatelet therapy, antihyperglycemic therapy, hypoglycemia, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), ASCVD, HF, CKD, and comorbid HF and CKD, as well as a graphical summary of medications used for DCRM.

Baylor College of Medicine Houston TX USA

Brigham and Women's Hospital Harvard Medical School Boston MA USA

David Geffen School of Medicine UCLA Los Angeles CA USA

Duke University Medical Center Durham NC USA

Emory University Atlanta GA USA

Grunberger Diabetes Institute Bloomfield Hills MI USA Wayne State University School of Medicine Detroit MI USA Oakland University William Beaumont School of Medicine Rochester MI USA Charles University Prague Czech Republic

Johns Hopkins University School of Medicine Baltimore MD USA

Metabolic Institute of America Tarzana CA USA

Mount Sinai School of Medicine New York NY USA

Saint Luke's Mid America Heart Institute University of Missouri Kansas City Kansas City MO USA

Scripps Whittier Institute for Diabetes San Diego CA USA

The Center for Diabetes and Endocrine Care University of Miami Miller School of Medicine Hollywood FL USA

The Frist Clinic Nashville TN USA

Tulane University Health Sciences Center New Orleans LA USA

University of California at Irvine Irvine CA USA

University of California San Diego School of Medicine San Diego CA USA

University of Chicago Medicine Chicago IL USA

University of Colorado Anschutz Medical Campus Denver CO USA

University of Maryland School of Medicine Baltimore MD USA

University of Mississippi Medical Center Jackson MS USA

University of Tennessee Health Science Center Memphis TN USA

University of Texas Health Science Center San Antonio TX USA

University of Washington Seattle WA USA

Vanderbilt University Medical Center Nashville TN USA

Yale School of Medicine New Haven CT USA

Zobrazit více v PubMed

Centers for Disease Control and Prevention. Chronic kidney disease surveillance system—United States; https://nccd.cdc.gov/CKD/. Accessed 19 November 2019.

Centers for Disease Control and Prevention. National diabetes statistics report, 2017. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services; 2017.

Plantinga LC, Crews DC, Coresh J, et al. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol. 2010;5: 673–682. PubMed PMC

Kidney Disease: Improving Global Outcomes CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150. PubMed

Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the american Association of Clinical Endocrinologists and American College of endocrinology on the comprehensive type 2 diabetes management algorithm—2020 executive summary. Endocr Pract. 2020;26:107–139. PubMed

Handelsman Y, Jellinger PS, Guerin CK, et al. Consensus statement by the american Association of Clinical Endocrinologists and American College of endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm—2020 executive summary. Endocr Pract. 2020; 26:1196–1224. PubMed

Kidney, Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2020;98, s1–s115. PubMed

GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1151–1210. PubMed PMC

Bhatnagar P, Wickramasinghe K, Wilkins E, Townsend N. Trends in the epidemiology of cardiovascular disease in the UK. Heart. 2016;102:1945–1952. PubMed PMC

Virani SS, Alonso A, Aparicio HJ, et al. Heart disease and stroke statistics—2021 update: a report from the American Heart Association. Circulation. 2021;143: e254–e743. PubMed

Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22: 1–203. PubMed

Bazzano LA, He J, Ogden LG, et al. Fruit and vegetable intake and risk of cardiovascular disease in US adults: the first National Health and nutrition examination survey epidemiologic follow-up study. Am J Clin Nutr. 2002;76: 93–99. PubMed

Chiavaroli L, Viguiliouk E, Nishi SK, et al. DASH dietary pattern and cardiometabolic outcomes: an umbrella review of systematic reviews and meta-analyses. Nutrients. 2019;11. PubMed PMC

Price DA, Deng Q, Kipnes M, Beck SE. Episodic real-time CGM use in adults with type 2 diabetes: results of a pilot randomized controlled trial. Diabetes Ther. 2021; 12:2089–2099. PubMed PMC

Bergenstal RM, Layne JE, Zisser H, et al. Remote application and use of real-time continuous glucose monitoring by adults with type 2 diabetes in a virtual diabetes clinic. Diabetes Technol Ther. 2021;23:128–132. PubMed PMC

Cappuccio FP, Cooper D, D’Elia L, Strazzullo P, Miller MA. Sleep duration predicts cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. Eur Heart J. 2011;32:1484–1492. PubMed

Valencia-Flores M, Orea A, Castano VA, et al. Prevalence of sleep apnea and electrocardiographic disturbances in morbidly obese patients. Obes Res. 2000;8: 262–269. PubMed

American Heart Association. Is drinking alcohol part of a healthy lifestyle?. https://www.heart.org/en/healthy-living/healthy-eating/eat-smart/nutrition-basics/alcohol-and-heart-health; 2019. Accessed 24 November 2021.

Stalnikowicz R, Brezis M. Meaningful shared decision-making: complex process demanding cognitive and emotional skills. J Eval Clin Pract. 2020;26:431–438. PubMed

Bischof G, Bischof A, Rumpf HJ. Motivational interviewing: an evidence-based approach for use in medical practice. Dtsch Arztebl Int. 2021;118:109–115. PubMed PMC

Emberson MA, Lalande A, Wang D, McDonough DJ, Liu W, Gao Z. Effectiveness of smartphone-based physical activity interventions on individuals’ health outcomes: a systematic review. Biomed Res Int. 2021;2021, 6296896. PubMed PMC

Schoeppe S, Alley S, Van Lippevelde W, et al. Efficacy of interventions that use apps to improve diet, physical activity and sedentary behaviour: a systematic review. Int J Behav Nutr Phys Act. 2016;13:127. PubMed PMC

Brickwood KJ, Watson G, O’Brien J, Williams AD. Consumer-based wearable activity trackers increase physical activity participation: systematic review and meta-analysis. JMIR Mhealth Uhealth. 2019;7, e11819. PubMed PMC

Cohen JB, Denker MG, Cohen DL, Townsend RR. Cardiovascular events and mortality in white coat hypertension. Ann Intern Med. 2019;171:603–604. PubMed PMC

Cohen JB, Cohen DL. Integrating out-of-office blood pressure in the diagnosis and management of hypertension. Curr Cardiol Rep. 2016;18:112. PubMed PMC

American Diabetes Association. 7. Diabetes technology: standards of medical care in diabetes—2021. Diabetes Care. 2021;44, S85–s99. PubMed

Grunberger G, Sherr J, Allende M, et al. American Association of Clinical Endocrinology clinical practice guideline: the use of advanced technology in the management of persons with diabetes mellitus. Endocr Pract. 2021;27:505–537. PubMed

Parkin CG, Buskirk A, Hinnen DA, Axel-Schweitzer M. Results that matter: structured vs. Unstructured self-monitoring of blood glucose in type 2 diabetes. Diabetes Res Clin Pract. 2012;97:6–15. PubMed

Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; world heart federation; international atherosclerosis society; and International Association for the Study of obesity. Circulation. 2009;120: 1640–1645. PubMed

American Diabetes Association. 11. Microvascular complications and foot care: standards of medical care in diabetes—2021. Diabetes Care. 2021;44, S151–s167. PubMed

American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes—2021. Diabetes Care. 2021;44, S125–s150. PubMed

Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003; 52:102–110. PubMed

Dagogo-Jack S, Askari H, Tykodi G. Glucoregulatory physiology in subjects with low-normal, high-normal, or impaired fasting glucose. J Clin Endocrinol Metab. 2009;94:2031–2036. PubMed PMC

Sallar A, Dagogo-Jack S. Regression from prediabetes to normal glucose regulation: state of the science. Exp Biol Med (Maywood). 2020;245:889–896. PubMed PMC

American Diabetes Association. 8. Obesity management for the treatment of type 2 diabetes: standards of medical care in diabetes—2021. Diabetes Care. 2021;44, S100–s110. PubMed

Kahn SE, Lachin JM, Zinman B, et al. Effects of rosiglitazone, glyburide, and metformin on beta-cell function and insulin sensitivity in ADOPT. Diabetes. 2011; 60:1552–1560. PubMed PMC

Diabetes Prevention Program Research Group, Ratner R, Goldberg R. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care. 2005;28:888–894. PubMed PMC

STOP-NIDDM Trial Research Group, Chiasson JL, Josse RG, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072–2077. PubMed

DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364:1104–1115. PubMed

McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995–2008. PubMed

Papaetis GS. Liraglutide therapy in a prediabetic state: rethinking the evidence. Curr Diabetes Rev. 2020;16:699–715. PubMed

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th Edition (DSM-5). Washington, DC: American Psychiatric Publishing; 2013.

Jorm AF, Jolley D. The incidence of dementia: a meta-analysis. Neurology. 1998;51: 728–733. PubMed

Hugo J, Ganguli M. Dementia and cognitive impairment: epidemiology, diagnosis, and treatment. Clin Geriatr Med. 2014;30:421–442. PubMed PMC

Gudala K, Bansal D, Schifano F, Bhansali A. Diabetes mellitus and risk of dementia: a meta-analysis of prospective observational studies. J Diabetes Investig. 2013;4: 640–650. PubMed PMC

Rusanen M, Kivipelto M, Levalahti E, et al. Heart diseases and long-term risk of dementia and Alzheimer’s disease: a population-based CAIDE study. J Alzheimers Dis. 2014;42:183–191. PubMed

Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA. 2009;301:1565–1572. PubMed PMC

Lin FR, Albert M. Hearing loss and dementia—who is listening? Aging Ment Health. 2014;18:671–673. PubMed PMC

Rabinovici GD. Controversy and progress in Alzheimer’s Disease—FDA approval of aducanumab. N Engl J Med. 2021;385:771–774. PubMed

Du P, Li D, Wang A, Shen S, Ma Z, Li X. A systematic review and meta-analysis of risk factors associated with severity and death in COVID-19 patients. Can J Infect Dis Med Microbiol. 2021;2021, 6660930. PubMed PMC

Grohskopf LA, Alyanak E, Ferdinands JM, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices, United States, 2021–22 influenza season. MMWR Recomm Rep. 2021;70:1–28. PubMed PMC

Centers for Disease Control and Prevention. COVID-19 vaccines for people with underlying medical conditions. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/underlying-conditions.html; 2021. Accessed 29 September 2021.

Immunization Action Coalition. Handouts for patients & staff: vaccinations for adults with diabetes and Vaccinations for adults with heart disease. https://www.immunize.org/handouts/view-all.asp; 2020. Accessed 29 September 2021.

Michos ED, Udell JA. Am I getting the influenza shot too?: influenza vaccination as post-myocardial infarction care for the prevention of cardiovascular events and death. Circulation. 2021;144:1485–1488. PubMed

Keri VC, Hooda A, Kodan P, LB R, Jorwal P, Wig N. Intricate interplay between COVID-19 and cardiovascular diseases. Rev Med Virol. 2021;31(4), e2188. PubMed

Lowenstein CJ, Solomon SD. Severe COVID-19 is a microvascular disease. Circulation. 2020;142:1609–1611. PubMed PMC

Hultström M, Lipcsey M, Wallin E, Larsson IM, Larsson A, Frithiof R. Severe acute kidney injury associated with progression of chronic kidney disease after critical COVID-19. Crit Care. 2021;25:37. PubMed PMC

Yedlapati SH, Khan SU, Talluri S, et al. Effects of influenza vaccine on mortality and cardiovascular outcomes in patients with cardiovascular disease: a systematic review and meta-analysis. J Am Heart Assoc. 2021;10, e019636. PubMed PMC

Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the american College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;73: e285–e350. PubMed

Tridandapani S, Banait-Deshmane S, Aziz MU, Bhatti P, Singh SP. Coronary computed tomographic angiography: a review of the techniques, protocols, pitfalls, and radiation dose. J Med Imaging Radiat Sci. 2021;52(3S):S1–S11. PubMed

Craven TP, Tsao CW, La Gerche A, Simonetti OP, Greenwood JP. Exercise cardiovascular magnetic resonance: development, current utility and future applications. J Cardiovasc Magn Reson. 2020;22:65. PubMed PMC

Brott Thomas G, Halperin Jonathan L, Abbara S, et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease. J Am Coll Cardiol. 2011;57:e16–e94. PubMed

Gerhard-Herman Marie D, Gornik Heather L, Barrett C, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease. J Am Coll Cardiol. 2017;69:e71–e126. PubMed

Yancy Clyde W, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the Management of Heart Failure. J Am Coll Cardiol. 2013;62:e147–e239. PubMed

Yancy Clyde W, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the Management of Heart Failure. J Am Coll Cardiol. 2017;70:776–803. PubMed

Jellinger PS, Handelsman Y, Bell DS, et al. American Association of Clinical Endocrinologists and American College of endocrinology guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocr Pract. 2017; 23:1–87. PubMed

Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097–2107. PubMed

Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–1722. PubMed

Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–2397. PubMed

Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23:1–87. PubMed

Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–188. PubMed

McClelland RL, Jorgensen NW, Budoff M, et al. 10-year coronary heart disease risk prediction using coronary artery calcium and traditional risk factors: derivation in the MESA (Multi-ethnic study of Atherosclerosis) with validation in the HNR (Heinz nixdorf Recall) study and the DHS (Dallas heart Study). J Am Coll Cardiol. 2015;66:1643–1653. PubMed PMC

Lloyd-Jones DM, Wilson PW, Larson MG, et al. Framingham risk score and prediction of lifetime risk for coronary heart disease. Am J Cardiol. 2004;94:20–24. PubMed

Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. JAMA. 2007;297:611–619. PubMed

Stevens RJ, Kothari V, Adler AI, Stratton IM. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond). 2001;101:671–679. PubMed

Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the american College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2013; 129:S49–S73. PubMed

Shao H, Fonseca V, Stoecker C, Liu S, Shi L. Novel risk engine for diabetes progression and mortality in USA: building, relating, assessing, and validating outcomes (BRAVO). Pharmacoeconomics. 2018;36:1125–1134. PubMed PMC

SCORE2 Working Group, ESC Cardiovascular Risk Collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42:2439–2454. PubMed PMC

Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383:711–720. PubMed

Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285: 2486–2497. PubMed

Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014; 384:626–635. PubMed

Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–1861. PubMed

Tenkanen L, Manttari M, Kovanen PT, Virkkunen H, Manninen V. Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki heart study. Arch Intern Med. 2006;166:743–748. PubMed

Elam M, Lovato L, Ginsberg H. The ACCORD-lipid study: implications for treatment of dyslipidemia in type 2 diabetes mellitus. Clin Lipidol. 2011;6:9–20. PubMed PMC

Ginsberg HN. The ACCORD (Action to control cardiovascular risk in Diabetes) lipid trial: what we learn from subgroup analyses. Diabetes Care. 2011;34:S107–S108. PubMed PMC

Woo Y, Shin JS, Shim CY, et al. Effect of fenofibrate in 1113 patients at low-density lipoprotein cholesterol goal but high triglyceride levels: real-world results and factors associated with triglyceride reduction. PLoS One. 2018;13, e0205006. PubMed PMC

Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11–22. PubMed

Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2018;71, e127. PubMed

Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the european Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39:3021–3104. PubMed

Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The modification of diet in renal disease study. Ann Intern Med. 1995;123:754–762. PubMed

Kalaitzidis RG, Bakris GL. Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease? Curr Opin Nephrol Hypertens. 2009;18:386–391. PubMed

Burnier M, Bakris G, Williams B. Redefining diuretics use in hypertension: why select a thiazide-like diuretic? J Hypertens. 2019;37:1574–1586. PubMed PMC

Bakris GL, Weir MR, Secic M, Campbell B, Weis-McNulty A. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int. 2004;65:1991–2002. PubMed

Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care. 1993;16:434–444. PubMed

Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000; 160:685–693. PubMed

Kim HJ, Shin JH, Lee Y, et al. Clinical features and predictors of masked uncontrolled hypertension from the korean ambulatory blood pressure monitoring registry. Korean J Intern Med. 2021;36:1102–1114. PubMed PMC

Group ASC, Bowman L, Mafham M, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379:1529–1539. PubMed

Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502. PubMed

Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–2015. PubMed

Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–1057. PubMed

Granger CB, Berger PB. Understanding the adverse effects of ticagrelor in practice. JAMA Cardiol. 2016;1:381–383. PubMed

Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377:1319–1330. PubMed

Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791–1800. PubMed

Steg PG, Bhatt DL, Simon T, et al. Ticagrelor in patients with stable coronary disease and diabetes. N Engl J Med. 2019;381:1309–1320. PubMed

Bhatt DL, Steg PG, Mehta SR, et al. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet. 2019;394:1169–1180. PubMed

Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020;382:1994–2004. PubMed

CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348: 1329–1339. PubMed

Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228–1239. PubMed PMC

Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–2257. PubMed

Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381:841–851. PubMed

Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322. PubMed PMC

Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–1844. PubMed

Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-ontrolled trial. Lancet. 2019;394:121–130. PubMed

Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392: 1519–1529. PubMed

Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–334. PubMed

Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128. PubMed

Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–657. PubMed

Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347–357. PubMed

Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384:117–128. PubMed

Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384:129–139. PubMed

Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295–2306. PubMed

Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383:1425–1435. PubMed

Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451–1461. PubMed

Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413–1424. PubMed

Nassif ME, Windsor SL, Tang F, et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial. Circulation. 2019;140:1463–1476. PubMed

Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436–1446. PubMed

Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macroVascular Events): a randomized controlled trial. Lancet. 2005;366:1279–1289. PubMed

Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374:1321–1331. PubMed PMC

American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2021. Diabetes Care. 2021;44, S111–s124. PubMed

American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes—2021. Diabetes Care. 2021;44, S73–s84. PubMed

Desouza CV, Holcomb RG, Rosenstock J, et al. Results of a study comparing glycated albumin to other glycemic indices. J Clin Endocrinol Metab. 2020;105: 677–687. PubMed PMC

Agiostratidou G, Anhalt H, Ball D. Standardizing clinically meaningful outcome measures beyond HbA1c for type 1 diabetes: a consensus report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange. Diabetes Care. 2017;40:1622–1630. PubMed PMC

Goto A, Arah OA, Goto M, Terauchi Y, Noda M. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ. 2013;347, f4533. PubMed

McCoy RG, Van Houten HK, Ziegenfuss JY, Shah ND, Wermers RA, Smith SA. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care. 2012;35:1897–1901. PubMed PMC

Brod M, Christensen T, Thomsen TL, Bushnell DM. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health. 2011;14:665–671. PubMed

Russell-Jones D, Pouwer F, Khunti K. Identification of barriers to insulin therapy and approaches to overcoming them. Diabetes Obes Metab. 2018;20:488–496. PubMed PMC

Mercado CI, Gregg EW, Ali MK, Saydah SH, Imperatore G, McKeever Bullard K. Differences in U.S. rural-urban trends in diabetes ABCS, 1999–2018. Diabetes Care. 2021;44:1766–1773. Accessed 24 November 2021. PubMed PMC

Chen Y, Rolka D, Xie H, Saydah S. Imputed state-level prevalence of achieving goals to prevent complications of diabetes in adults with self-reported diabetes—United States, 2017–2018. MMWR. 2020;69:1665–1670. PubMed PMC

Bonds DE, Miller ME, Bergenstal RM. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010;340, b4909-b4909. PubMed PMC

Kedia N. Treatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approach. Diabetes Metab Syndr Obes. 2011;4:337–346. PubMed PMC

Newswanger B, Prestrelski S, Andre AD. Human factors studies of a prefilled syringe with stable liquid glucagon in a simulated severe hypoglycemia rescue situation. Expert Opin Drug Deliv. 2019;16:1015–1025. PubMed

Méndez-Sánchez N, Díaz-Orozco LE. Editorial: international consensus recommendations to replace the terminology of non-alcoholic fatty liver disease (NAFLD) with metabolic-associated fatty liver disease (MAFLD). Med Sci Monit. 2021;27, e933860. PubMed PMC

Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202–209. PubMed

Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142: 1592–1609. PubMed

Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology. 2012; 142:711–725.e716. PubMed

Stefan N, Häring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 2019;7:313–324. PubMed

Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology (Baltimore, Md). 2018;67:328–357. PubMed

Verma S, Jensen D, Hart J, Mohanty SR. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver Int. 2013;33:1398–1405. PubMed

Kalsch J, Bechmann LP, Heider D, et al. Normal liver enzymes are correlated with severity of metabolic syndrome in a large population based cohort. Sci Rep. 2015;5: 13058. PubMed PMC

Bril F, Cusi K. Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action. Diabetes Care. 2017;40:419–430. PubMed

Musso G, Cassader M, Paschetta E, Gambino R. Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis. JAMA Intern Med. 2017;177:633–640. PubMed PMC

Bhatt DL, Brinton EA, Miller M, et al. 4-LB: substantial cardiovascular benefit from icosapent ethyl in patients with diabetes: REDUCE-IT DIABETES. Diabetes. 2020; 69:4-LB.

Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373: 1849–1860. PubMed PMC

Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the american College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America. Circulation. 2017;136: e137–e161. PubMed

Myhre PL, Vaduganathan M, Claggett B, et al. B-type natriuretic peptide during treatment with sacubitril/valsartan: the PARADIGM-HF trial. J Am Coll Cardiol. 2019;73:1264–1272. PubMed PMC

Berg DD, Wiviott SD, Scirica BM, et al. Heart failure risk stratification and efficacy of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus. Circulation. 2019;140:1569–1577. PubMed PMC

Segar MW, Vaduganathan M, Patel KV, et al. Machine learning to predict the risk of incident heart failure hospitalization among patients with diabetes: the WATCH-DM risk score. Diabetes Care. 2019;42:2298–2306. PubMed PMC

Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2013;62:e147–e239. PubMed

Vasan RS, Xanthakis V, Lyass A, et al. Epidemiology of left ventricular systolic dysfunction and heart failure in the Framingham study: an echocardiographic study over 3 decades. JACC Cardiovasc Imaging. 2018;11:1–11. PubMed PMC

Kanwar M, Walter C, Clarke M, Patarroyo-Aponte M. Targeting heart failure with preserved ejection fraction: current status and future prospects. Vasc Health Risk Manag. 2016;12:129–141. PubMed PMC

Huis In ‘t Veld AE, de Man FS, van Rossum AC, Handoko ML. How to diagnose heart failure with preserved ejection fraction: the value of invasive stress testing. Neth Hear J. 2016;24:244–251. PubMed PMC

Steinberg BA, Zhao X, Heidenreich PA, et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation. 2012;126:65–75. PubMed

Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017;3:7–11. PubMed PMC

Loudon BL, Noordali H, Gollop ND, Frenneaux MP, Madhani M. Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm. Br J Pharmacol. 2016;173(12):1911–1924. PubMed PMC

Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381:1609–1620. PubMed

Afkarian M, Zelnick LR, Hall YN, et al. Clinical manifestations of kidney disease among us adults with diabetes, 1988–2014. JAMA. 2016;316:602–610. PubMed PMC

de Boer IH. Kidney disease and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014;37:24–30. PubMed PMC

Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012;380(9854):1662–1673. PubMed PMC

Neumiller JJ, Alicic RZ, Tuttle KR. Therapeutic considerations for antihyperglycemic agents in diabetic kidney disease. J Am Soc Nephrol. 2017;28: 2263–2274. PubMed PMC

Delgado C, Baweja M, Crews DC, Eneanya ND, Gadegbeku CA, Inker LA, Mendu ML, Miller WG, Moxey-Mims MM, Roberts GV, St Peter WL, Warfield C, Powe NR. A unifying approach for GFR estimation: recommendations of the NKF-ASN task force on reassessing the inclusion of race in diagnosing kidney disease. Am J Kidney Dis; 2021. Sep 22. S0272-6386(21)00828-3 10.1053/j.ajkd.2021.08.003. Epub ahead of print. PMID: 34563581. PubMed DOI

Inker LA, Eneanya ND, Coresh J, et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med. 2021;385(19):1737–1749. PubMed PMC

Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care. 2015;21: S212–S220. PubMed

McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021;6:148–158. PubMed PMC

Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7:845–854. PubMed

Zoungas S, de Boer IH. SGLT2 inhibitors in diabetic kidney disease. Clin J Am Soc Nephrol. 2021;16:631–633. PubMed PMC

Packer M, Butler J, Zannad F, et al. Empagliflozin and major renal outcomes in heart failure. N Engl J Med. 2021;385:1531–1533. PubMed

Michos ED, Tuttle KR. GLP-1 receptor agonists in diabetic kidney disease. Clin J Am Soc Nephrol. 2021;16:1578–1580. PubMed PMC

Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219–2229. PubMed

Pitt B, Filippatos G, Agarwal R. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021. Aug 28. 10.1056/NEJMoa2110956. Online ahead of print. PubMed DOI

Agarwal R, Filipattos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J; 2021. Nov 22. Online ahead of print 10.1093/eurheartj/ehab777. PubMed DOI PMC

Zannad F, Rossignol P, Stough WG, et al. New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: considerations for trial design and regulatory approval. Int J Cardiol. 2016;216: 46–51. PubMed

Neuen BL, Oshima M, Perkovic V. Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. Eur Heart J. 2021. Aug 23, ehab497. 10.1093/eurheartj/ehab497. PubMed DOI

Mullens W, Damman K, Testani JM, et al. Evaluation of kidney function throughout the heart failure trajectory—a position statement from the heart failure Association of the European Society of cardiology. Eur J Heart Fail. 2020;22:584–603. PubMed

Jering KS, Zannad F, Claggett B, et al. Cardiovascular and renal outcomes of mineralocorticoid receptor antagonist use in PARAGON-HF. JACC Heart Fail. 2021; 9:13–24. PubMed

Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care. 2011;34:1431–1437. PubMed PMC

Singh AK, Kumar A, Karmakar D, Jha RK. Association of B12 deficiency and clinical neuropathy with metformin use in type 2 diabetes patients. J Postgrad Med. 2013; 59:253–257. PubMed

Diabetes Prevention Program Research Group, Knowler WC, Barrett-Connor E. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403. PubMed PMC

Davies M, Chatterjee S, Khunti K. The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies. Clin Pharmacol. 2016;8:61–81. PubMed PMC

Handelsman Y, Henry RR, Bloomgarden ZT, et al. American Association of Clinical Endocrinologists and American College of endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis. Endocr Pract. 2016;22: 753–762. PubMed

Viscoli CM, Inzucchi SE, Young LH, et al. Pioglitazone and risk for bone fracture: safety data from a randomized clinical trial. J Clin Endocrinol Metab. 2017;102: 914–922. PubMed PMC

Fonseca VA, Handelsman Y, Staels B. Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. Diabetes Obes Metab. 2010;12:384–392. PubMed PMC

Gaziano JM, Cincotta AH, Vinik A, Blonde L, Bohannon N, Scranton R. Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects. J Am Heart Assoc. 2012;1, e002279. PubMed PMC

Mach F, Ray KK, Wiklund O, et al. Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J. 2018;39:2526–2539. PubMed PMC

Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305: 2556–2564. PubMed

Barrera-Chimal J, Lima-Posada I, Bakris GL, Jaisser F. Mineralocorticoid receptor antagonists in diabetic kidney disease—mechanistic and therapeutic effects. Nature Rev Nephrol; 2021. Oct 23. Online ahead of print 10.1038/s41581-021-00490-8. PubMed DOI

Clarisse D, Deng L, de Bosscher K, Lother A. Approaches towards tissue-selective pharmacology of the mineralocorticoid receptor. Br J Pharmacol. 2021. Oct 26. 10.1111/bph.15719. PubMed DOI

McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004. PubMed

Spannella F, Giulietti F, Filipponi A, Sarzani R. Effect of sacubitril/valsartan on renal function: a systematic review and meta-analysis of randomized controlled trials. ESC Heart Fail. 2020;7:3487–3496. PubMed PMC

Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381:1609–1620. PubMed

Selvaraj S, Claggett BL, Packer M, et al. Effects of sacubitril/valsartan on serum lipids in heart failure with preserved ejection fraction. J Am Heart Assoc. 2021;10, e022069. PubMed PMC